



PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

29th July 2013 - New research

PRAMIPEXOLE : EXTENDED RELEASE v IMMEDIATE RELEASE

Drug Research [2013] Jul 24 [Epub ahead of print] (M.Takanashi, Y.Shimo, T.Hatano, G.Oyama, N.Hattori)

Changing from Immediate release Pramipexole to Extended release Pramipexole was found to cause a reduction in Parkinson's Disease symptoms. Pramipexole, which is marketed as Mirapex, Mirapexin, and Sifrol, is a dopamine agonist used in the treatment of Parkinson's Disease. For more information go to Mirapex <http://www.rxlist.com/mirapex-drug.htm> and Mirapex ER <http://www.rxlist.com/mirapex-er-drug.htm>

This study aimed to evaluate the efficacy and safety of an extended-release tablet formulation of pramipexole (PPX-ER) given once daily when switched from an immediate-release tablet formulation (PPX-IR) given 3 times daily. The extended release version evens out the effect of Pramipexole. Parkinson's Disease symptom scores were reduced after 4 weeks and after 8 weeks. There was no change in the nocturnal and early morning symptoms (NEMS) score, or the Parkinson's Disease Sleep Scale (PDSS-2). Nearly two thirds of patients and caregivers preferred the extended release version.

<http://www.viartis.net/parkinsons.disease/news/130729.pdf>

mail@viartis.net

©2013 Viartis